INTENT_Circulating tumor cells as biomarkers for recurrence risk in thermoablatio
Not Applicable
- Conditions
- C22.0Liver cell carcinoma
- Registration Number
- DRKS00016808
- Lead Sponsor
- Klinikum der Universität München, Campus Großhadern
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
a) treatment naïve HCC patients, BCLC 0 or A, maximum size of lesions <3cm
b) male/female, =18
c) indication for thermoablation
d) indication for TA according to multidisciplinary board decision
e) informed consent signed
Exclusion Criteria
a) age <18
b) other pre-existing malignancies
c) contraindication for resection or thermoablation
d) life expectation < 3 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of tumor cells and tumor genetic information in blood before and after therapy in HCC disease.<br>Time to progression (local or de novo) and the change in - circulating tumor cells before and after brachytherapy.<br>
- Secondary Outcome Measures
Name Time Method The depiction of immuno-phenotypes of tissues adjacent to TA intervention areas <br>- Correlation of HCC precursor lesions in baseline imaging and post ablation CTC burden<br>